Theregen to develop Anginera epicardial patch with Guidant funds

By Angela McDaniels

Seattle, Feb. 7 - Theregen Corp. has received an equity investment from Guidant Corp. to develop the Anginera epicardial patch, according to a company news release.

Theregen is developing Anginera as a treatment for diffuse small vessel coronary artery disease. The product will serve as an adjunct therapy to revascularization procedures such as coronary artery bypass graft surgery.

In 2005, Theregen received FDA approval to proceed with a phase 1 safety trial, which the company intends to begin this quarter.

"We believe our Anginera therapy has the potential to benefit patients suffering from a variety of chronic, debilitating cardiovascular diseases," Theregen chief executive officer Thomas A. Schreck said in the release.

Theregen is a San Francisco-based regenerative medicine company that develops cell-based therapies for patients with cardiovascular and vascular disease.

Guidant, based in Indianapolis, develops therapies for cardiac and vascular disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.